Warning: mkdir(): Permission denied in /home/virtual/lib/view_data.php on line 81 Warning: fopen(/home/virtual/e-apem/journal/upload/ip_log/ip_log_2022-12.txt): failed to open stream: No such file or directory in /home/virtual/lib/view_data.php on line 83 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 84 The effect of metformin on vitamin B12 level in pediatric patients
Ann Pediatr Endocrinol Metab Search


Ann Pediatr Endocrinol Metab > Volume 27(3); 2022 > Article
Yu, So, and Khallouq: The effect of metformin on vitamin B12 level in pediatric patients



Metformin is a common medication for patients with hyperglycemia. In adults, one well-documented side effect of metformin is vitamin B12 deficiency. However, this side effect has rarely been studied in pediatric patients. This study examined the changes of vitamin B12 level in pediatric patients being treated with metformin.


Data were collected from pediatric patients (n=151) with at least 3 months of consecutive metformin intake. The effects of dose of metformin on the mean vitamin B12 level were investigated at 6, 12, 24, and 36 months. The effect of compliance of metformin intake on vitamin B12 level also was studied.


There was no significant decrease in mean vitamin B12 level at 6, 12, 24, or 36 months in patients treated with metformin. Mean vitamin B12 decrease was only noticeable (P<0.05) in patients taking a high dose of metformin with good compliance. Despite this change, the mean vitamin B12 remained well within the normal reference range. Furthermore, of the 151 patients studied, only 1 demonstrated vitamin B12 deficiency after 12 months of treatment. However, his B12 level was normal at 24 and 36 months without any vitamin B12 supplements.


Our findings suggest that metformin treatment in children does not cause vitamin B12 deficiency; however, the effect of long-term consistent high-dose treatment on vitamin B12 level remains unknown.


· This is so far the first study looking at the effect on metformin on vitamin B12 level in children. This study examined the difference on metformin treatment on vitamin B12 level in relation to dosage and duration.


In the United States, the prevalence of type 2 diabetes mellitus (T2DM) has increased threefold in adults as well as in children, with approximately 12 of every 100,000 children impacted [1,2]. A common treatment plan for T2DM patients involves metformin oral therapy in conjunction with life-style changes for weight control [3,4]. Metformin’s antihyperglycemic action is thought to suppress hepatic gluconeogenesis [5]. Metformin is currently one of the most common pharmacological agents approved for pediatric T2DM [6,7]. The use of metformin is well known to extend to other metabolic problems associated with obesity, such as mild dysglycemia and polycystic ovarian syndrome [4,8,9].
Known side effects of metformin include but are not limited to gastrointestinal distress, soft stools, diarrhea, and lactic acidosis [10,11]. A more controversial side effect is vitamin B12 deficiency. In adults, studies have shown that metformin can lower vitamin B12 level and potentially cause vitamin B12 deficiency in a dose- and duration-dependent manner [10-20]. There has rarely been any direct study of this potential problem in pediatric patients. As more and more children are treated with metformin [1], there is valid concern about vitamin B12 deficiency. Furthermore, previous work has indicated a potential decrease in vitamin B12 level in certain patients such as obese children even without metformin treatment [21].
Vitamin B12 deficiency is of great concern as it is the most common cause of megaloblastic anemia. Other problems associated with vitamin B12 deficiency include neurological abnormalities and sensory-motor deficiency [15,22]. As children undergo rapid development, failure to recognize or treat vitamin B12 deficiency could delay development in fine motor and gross motor skills and in cognition [15]. Thus, establishing and understanding the relationship between metformin treatment and vitamin B12 deficiency in pediatric patients is important. The aim of this study is to explore the possible effects of metformin dose and duration on vitamin B12 level in pediatric patients.

Materials and methods

This was a retrospective study utilizing data of pediatric patients from Nemours Children's Hospital in Orlando, Florida, USA, from January 2000 to July 2015, extracted from the electronic patient record system (EPIC). Clinical variables were metformin dosage, compliance, and vitamin B12 levels.

1. Patient inclusion

A total of 151 pediatric patients aged 6–17 years who had been prescribed metformin for at least 3 consecutive months and underwent more than 1 vitamin B12 level measurement during treatment was included. Both genders were included (32 males, 119 females). The ethnicities recorded in the system were 55 White, 30 Black, 34 Hispanic, 4 Asian, 9 others, and 19 unidentified.

2. Exclusion

Most patients selected had vitamin B12 level measured at Quest Diagnostics. Children who were hypercobalaminemic (defined as >950 pg/mL) or hypocobalaminemic (defined as <200 pg/mL) prior to treatment or who were taking vitamin B12 or multivitamin supplements were excluded.

3. Vitamin B12 level

Vitamin B12 level was measured mostly at Quest Diagnostics Lab using an immunoassay. Based on the Quest Diagnostics reference ranges for 5–9-year-old children (250–1,205 pg/mL) and 10–17-year-old adolescents (200–935 pg/mL), vitamin B12 deficiency was defined as a serum level <200 pg/mL. Vitamin B12 level was recorded at start of metformin treatment (month 0, baseline) and at approximately 6, 12, 24, and 36 months of treatment.

4. Dosage assessment

For patients included in this study, dosages of metformin ranged from 500 to 2,000 mg/day. For easier analysis, we assigned "high dose" as >1,000 mg/day (n=26, 17%) and "low dose" as ≤1,000 mg/day (n=125, 83%). For cases with dosage changes during treatment, the most frequently used metformin dosage (prior to a vitamin B12 blood test) was recorded.

5. Compliance assessment

Compliance assessment was based on chart documentation and review of the prescription refills of metformin. No evidence of missing doses and filling most refills on time were defined as "good compliance." Intermittent intake of metformin, with occasionally missed doses and refills, was defined as "fair compliance." Frequently missed dose and failure to obtain refills were defined as "poor compliance."

6. Statistical analysis

In the first set of analyses, planned t-test comparisons were performed between baseline vitamin B12 level (month 0) and that at 6, 12, 24, and 36 months. As a second step, compliance and dosage were used separately to stratify the sample and repeat these analyses. As a final step, the combination of dosage and compliance was used to divide the patients into 3 groups: high dose and good compliance, low dose and good compliance, and low dose and poor compliance. Due to small sample size (n=2), the high dose and poor compliance group was not assessed. Vitamin B12 level is reported as mean±standard deviation, and dosage is reported as frequency and percentage. Statistical analyses were performed with IBM SPSS Statistics ver. 23.0 (IBM Co., Armonk, NY, USA). T-tests were 2-tailed, and a P≤0.05 was considered statistically significant.


1. Vitamin B12 changes with metformin treatment

A total of 151 patients between 6 and 17 years of age was included in analyses. The changes of mean vitamin B12 level after metformin treatment are shown in Tables 1 and 2. Compared with baseline, there was a general decreasing trend of vitamin B12 level at all treatment months (6, 12, 24, and 36 months) although none of the changes reached statistical significance.

2. The effect of compliance on level of vitamin B12

Patients with good compliance with metformin treatment showed no significant change in vitamin B12 level at 6 and 12 months. However, a decrease in B12 level was apparent at 24 and 36 months, even though neither change was statistically significant (Table 3).
Patients with fair compliance showed minor vitamin B12 level fluctuations after up to 24 months of treatment. At 36 months, the decrease in vitamin B12 level was more pronounced at -131.91 pg/mL but still was not significant (Table 3). Similar to the groups with good and fair compliance, patients with poor compliance showed no decrease in vitamin B12 level (Table 3).

3. The effect of dosage on level of vitamin B12

There were no significant decreases in level of vitamin B12 for patients in the low-dose metformin treatment, as shown in Table 4. For patients in the high-dose group, the vitamin B12 level decreased at every treatment interval. Although the decrease was not significant at 6 or 12 months, a significant decline was observed at 24 and 36 months after treatment.

4. The combined effect of dosage and compliance on level of vitamin B12

The combined effects of dosage and compliance also were investigated for 3 groups: high dose with good compliance, low dose with good compliance, and low dose with poor compliance. Although patients on a high dose with good compliance showed a noted decrease of vitamin B12 level at every treatment follow up, the observed decrease was significant only at 24 and 36 months, as shown in Table 5. Patients receiving a low dose with either good or poor compliance demonstrated no statistically significant changes in vitamin B12 level over time.


Except for one case, our study showed that metformin treatment in pediatric patients did not cause vitamin B12 deficiency throughout the duration of our study (36 months). Vitamin B12 in that patient spontaneously returned to the normal range at 24 and 36 months of treatment. This indicates that the patient's temporary vitamin B12 deficiency was likely due to factors unrelated to the metformin treatment.
Our study demonstrated a mild decrease in mean vitamin B12 level for patients who received a higher dose of metformin with good compliance over a longer treatment duration. Though this is the first study in pediatric patients, similar findings were observed in an adult study. A previous study indicated a duration-dependent decrease in vitamin B12 level with metformin treatment in adult patients [1]. In that study, vitamin B12 level decreased over the treatment duration, especially when the treatment was longer than 4 years. Another study found vitamin B12 level to decrease after a short metformin treatment duration of 6–12 weeks [12], although the drop was not as drastic as that in the previous study. The maximum treatment duration in our study was 3 years. While it seems meaningful to verify the effect beyond 3 years, pediatric patients typically do not taken metformin for this length of duration because hyperglycemia commonly develops in at older pediatric age.
The cause of vitamin B12 malabsorption due to metformin treatment might be metformin-induced digestive changes that lead to difficulty of intrinsic factor (IF) binding with vitamin B12, hindering its absorption [16]. Thus, it is understandable that the higher is the dose of metformin, the greater is the interference of IF binding with vitamin B12, leading to greater vitamin B12 malabsorption and a lower level of serum B12 level over time.
Overall, our study indicates that vitamin B12 deficiency does not occur in pediatric patients receiving metformin treatment over a 3-year period. Although metformin in our study was safe, the negative effect on B12 level in our study suggests the importance of monitoring vitamin B12 level, especially when a high dose of metformin is used over an extended treatment time. Adult studies recommend vitamin B12 screening for patients prescribed metformin [17,19]. However, a study on adults has shown obvious cases of vitamin B12 deficiency [13]. Some researchers have suggested an annual vitamin B12 supplement instead of annual screening [23]. Considering the low incidence of true B12 deficiency as well as the potential for compliance issues commonly encountered in adolescents, we think that a B12 supplement should not replace B12 monitoring in the pediatric population.
The strength of our study lies in the use of patient data from real clinic environments. However, this also produces many limitations common in retrospective analysis, with no control of individual variations over dosage compliance as well as other underlying conditions. Along with the concern about B12 level, the effects of long-term metformin treatment on hemoglobin, hematocrit, and homocysteine levels as well as possible neuropathy remain unknown. As our study is retrospective and complete blood count homocysteine level was not routinely measured in patients treated with metformin, these data are lacking and could not be assessed. There was no report of neuropathy from any of our study subjects. A prospective study should be designed to examine the dose and duration effects in a controlled manner as well as possible effects on hemoglobin, hematocrit, and homocysteine levels.
Our study suggests that metformin treatment in pediatric patients is generally safe and does not play a significant role in vitamin B12 deficiency. However, a mild decrease in vitamin B12 level in patients receiving higher metformin dose over a longer treatment duration calls for caution in pediatric populations. This finding suggests benefits in monitoring pediatric serum vitamin B12 level, especially when using a high dose for longer duration. This suggestion is reinforced by the increasingly common use of metformin among obese children with metabolic problems such as T2DM [3,4,8,9,24].

Ethical statement

This study was approved by the Institutional Review Boards at Nemours Children’s Hospital (IRB No. 775776-1) and the University of Central Florida (SBE-15-11616).


Conflicts of interest

No potential conflict of interest relevant to this article was reported.


This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author contribution

Conceptualization: YMY; Data curation: YMY; Formal analysis: YMY; Funding acquisition: SS; Project administration: YMY; Visualization: YMY; Writing - original draft: YMY; Writing - review & editing: YMY, SS, BK


We thank the Nemours' EPIC team for extracting patient data from the electronic medical records. We thank the faculty and staff at the University of Central Florida, College of Medicine, and the Focused Inquiry Research Experience (FIRE) Module for their feedback and support at the early stages of this project. We also thank Timothy Maul and Stuart Chalew for reviewing our manuscript and providing suggestions.

Table 1.
Descriptive statistics of vitamin B12 levels across time
Duration of treatment Vitamin B12 level (pg/mL)
Mean±SD Median (range)
6 Months 504.37±138 408.00 (208–916)
12 Months 531.00±175 538.00 (192–926)
24 Months 511.85±153 499.50 (270–926)
36 Months 487.88±158 466.50 (235–873)

SD, standard deviation.

Table 2.
Vitamin B12 level changes across time while on metformin treatment
Duration of treatment Vitamin B12 level (pg/mL)
P-value (2-tailed)
MD (95% CI) SEM
0 Month 0 N/A Reference group
6 Months -31.78 (-15.34 to 78.91) 23.85 0.185
12 Months -4.92 (-49.06 to 58.90) 27.32 0.857
24 Months -24.51 (-24.25 to 73.26) 24.69 0.322
36 Months -48.28 (-7.44 to 103.99) 28.16 0.089

MD, mean difference; CI, confidence interval; SEM, standard error of the mean; N/A, not available.

Table 3.
Changes in vitamin B12 across time intervals and levels of compliance
Duration of treatment Vitamin B12 level (pg/mL)
P-value (2-tailed)
Mean±SD MD (95% CI) SED
Good compliance (n=92)
 Baseline 517.79±132.79 0 N/A N/A
 6 Months 494.91±129.36 -22.88 (-30.28 to 76.03) 26.78 0.395
 12 Months 522.02±172.83 +4.23 (-68.55 to 60.09) 32.38 0.896
 24 Months 477.98±135.42 -39.81 (-15.93 to 95.54) 28.05 0.159
 36 Months 472.03±141.70 -45.76 (-17.55 to 109.06) 31.76 0.154
Fair compliance (n=29)
 Baseline 583.71±171.47 0 N/A N/A
 6 Months 519.67±150.00 -64.04 (-50.26 to 178.34) 55.97 0.262
 12 Months 550.13±139.28 -33.57 (-80.21 to 147.35) 55.71 0.551
 24 Months 550.95±153.86 -32.76 (-75.83 to 141.35) 53.49 0.544
 36 Months 451.80±159.96 -131.91 (-5.51 to 269.32) 66.72 0.059
Poor compliance (n=30)
 Baseline 533.50±211.40 0 N/A N/A
 6 Months 528.58±211.40 -4.92 (-154.26 to 164.09) 77.12 0.950
 12 Months 544.85±266.96 +11.35 (-185.07 to 162.38) 84.35 0.894
 24 Months 553.27±177.32 +19.77 (-152.52 to 112.98) 65.32 0.764
 36 Months 555.85±185.78 +22.35 (-180.61 to 135.92) 76.84 0.774

SD, standard deviation; MD, mean difference; CI, confidence interval; SED, standard error difference; N/A, not available.

Table 4.
Changes in vitamin B12 across time intervals and dosage
Dosage of treatment Vitamin B12 level (pg/mL)
P-value (2-tailed)
Mean±SD MD (95% CI) SED
Low dose (n=125)
 Baseline 528.31±158.36 0 N/A N/A
 6 Months 504.81±147.97 -23.50 (-30.34 to 77.33) 27.20 0.389
 12 Months 533.40±183.31 5.09 (-66.29 to 56.10) 30.91 0.869
 24 Months 526.27±155.70 -2.03 (-52.13 to 56.20) 27.38 0.941
 36 Months 509.75±164.68 -18.56 (-45.09 to 82.20) 32.09 0.564
High dose (n=26)
 Baseline 569.21±163.86 0 N/A N/A
 6 Months 502.21±74.39 -67.00 (-31.86 to 165.86) 48.10 0.175
 12 Months 520.60±139.56 -48.61 (-67.09 to 164.32) 56.39 0.396
 24 Months 452.56±129.67 -116.66 (10.79 to 222.53) 51.84 0.032*
 36 Months 407.67±97.23 -161.55 (49.99 to 273.10) 54.05 0.006*

SD, standard deviation; MD, mean difference; CI, confidence interval; SED, standard error difference; N/A, not available.

* P<0.05, statistically significant differences.

Table 5.
Changes in vitamin B12 across time intervals and levels of compliance
Treatment group Vitamin B12 level (pg/mL)
P-value (2-tailed)
Mean±SD MD (95% CI) SED
High dose with good compliance
 Baseline 571.29±137.66 0 N/A N/A
 6 Months 536.44±59.89 -34.84 (-74.17 to 143.85) 50.83 0.504
 12 Months 524.75±125.00 -46.54 (-99.93 to 193.00) 67.80 0.505
 24 Months 429.56±97.06 -141.73 (16.12 to 267.34) 58.56 0.030*
 36 Months 398.75±80.49 -172.54 (48.86 to 296.21) 57.25 0.010*
Low dose with good compliance
 Baseline 507.09±130.68 0 N/A N/A
 6 Months 486.78±137.96 -20.30 (-39.91 to 80.52) 30.25 0.504
 12 Months 521.52±181.34 14.44 (-87.02 to 58.15) 36.45 0.693
 24 Months 488.61±141.19 -18.48 (-44.10 to 81.05) 31.41 0.558
 36 Months 495.48±150.07 -11.61 (-61.27 to 84.48) 36.41 0.751
Low dose with poor compliance
 Baseline 549.83±225.24 0 N/A N/A
 6 Months 539.45±180.51 -10.38 (-167.72 to 188.47) 56.64 0.905
 12 Months 560.42±229.68 10.58 (-203.17 to 182.01) 92.86 0.910
 24 Months 564.90±180.31 15.07 (-162.70 to 132.57) 72.29 0.836
 36 Months 562.58±192.37 12.75 (-190.08 to 164.58) 85.51 0.883

SD, standard deviation; MD, mean difference; CI, confidence interval; SED, standard error difference; N/A, not available.

* P<0.05, statistically significant differences.


1. Reinehr T. Type 2 diabetes mellitus in children and adolescents. World J Diabetes 2013;4:270–81.
crossref pmid pmc
2. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014;311:1778–86.
crossref pmid pmc
3. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122:253–70.
crossref pmid pmc pdf
4. van der Aa MP, Elst MA, van de Garde EM, van Mil EG, Knibbe CA, van der Vorst MM. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes 2016;6:e228.
crossref pmid pmc pdf
5. Ferrannini E. The target of metformin in type 2 diabetes. N Engl J Med 2014;371:1547–8.
crossref pmid
6. Smith JD, Mills E, Carlisle SE. Treatment of pediatric type 2 diabetes. Ann Pharmacother 2016;50:768–77.
crossref pmid pdf
7. Christensen ML, Franklin BE, Momper JD, Reed MD. Pediatric drug development programs for type 2 diabetes: a review. J Clin Pharmacol 2015;55:731–8.
crossref pmid
8. Boland CL, Harris JB, Harris KB. Pharmacological management of obesity in pediatric patients. Ann Pharmacother 2015;49:220–32.
crossref pmid pdf
9. Xu S, Xue Y. Pediatric obesity: causes, symptoms, prevention and treatment. Exp Ther Med 2016;11:15–20.
crossref pmid pmc
10. Tung ML, Tan LK. Long term use of metformin leading to vitamin B 12 deficiency. Diabetes Res Clin Pract 2014;104:e75–6.
crossref pmid
11. Kos E, Liszek MJ, Emanuele MA, Durazo-Arvizu R, Camacho P. Effect of metformin therapy on vitamin D and vitamin B12 levels in patients with type 2 diabetes mellitus. Endocr Pract 2012;18:179–84.
crossref pmid
12. Chapman LE, Darling AL, Brown JE. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 2016;42:316–27.
crossref pmid
13. Ko SH, Ko SH, Ahn YB, Song KH, Han KD, Park YM, et al. Association of vitamin B12 deficiency and metformin use in patients with type 2 diabetes. J Korean Med Sci 2014;29:965–72.
crossref pmid pmc pdf
14. Sánchez H, Masferrer D, Lera L, Arancibia E, Angel B, Albala C. Vitamin B12 deficiency associated with high doses od metformin in older people diabetic. Nutr Hosp 2014;29:1394. –400. (Spanish).
15. Dobrozsi S, Flood VH, Panepinto J, Scott JP, Brandow A. Vitamin B12 deficiency: the great masquerader. Pediatr Blood Cancer 2014;61:753–5.
crossref pmid pdf
16. Liu Q, Li S, Quan H, Li J. Vitamin B12 status in metformin treated patients: systematic review. PLoS One 2014;9:e100379.
crossref pmid pmc
17. Akinlade KS, Agbebaku SO, Rahamon SK, Balogun WO. Vitamin B12 levels in patients with type 2 diabetes mellitus on metformin. Ann Ib Postgrad Med 2015;13:79–83.
pmid pmc
18. Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP Jr. Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 2012;35:327–33.
pmid pmc
19. Beulens JW, Hart HE, Kuijs R, Kooijman-Buiting AM, Rutten GE. Influence of duration and dose of metformin on cobalamin deficiency in type 2 diabetes patients using metformin. Acta Diabetol 2015;52:47–53.
crossref pmid pdf
20. de Jager J, Kooy A, Lehert P, Wulffelé MG, van der Kolk J, Bets D, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010;340:c2181.
crossref pmid pmc
21. Ho M, Halim JH, Gow ML, El-Haddad N, Marzulli T, Baur LA, et al. Vitamin B12 in obese adolescents with clinical features of insulin resistance. Nutrients 2014;6:5611–8.
crossref pmid pmc
22. Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J 2010;103:265–7.
crossref pmid
23. Mahajan R, Gupta K. Revisiting metformin: annual vitamin B12 supplementation may become mandatory with long-term metformin use. J Young Pharm 2010;2:428–9.
crossref pmid pmc
24. Gao YQ, Gao M, Xue Y. Treatment of diabetes in children. Exp Ther Med 2016;11:1168–72.
crossref pmid pmc


Browse all articles >

Editorial Office
#510, DoosanBearstel 381, Gangnam-daero, Seocho-gu, Seoul 06620, Korea
Tel: +82-2-3471-4268    Fax: +82-2-3471-4269    E-mail: kspe.editor@gmail.com                

Copyright © 2022 by Korean Society of Pediatric Endocrinology.

Developed in M2PI

Close layer
prev next